Léčivé přípravky s CAR-T lymfocyty a jejich reálná dostupnost pro české a slovenské pacienty
| Title in English | Medicinal products with CAR-T lymphocytes and their availability for Czech and Slovak patients |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | CAR-T cell immunotherapy currently represents a form of personalized treatment for hematological malignancies such as relapsed or refractory B-lymphomas, multiple myeloma, or acute lymphoblastic leukemia. Its potential in the treatment of solid tumors is still the subject of intensive clinical research. As of June 2024, six CAR-T lymphocyte products are centrally authorised in the EU, but availability varies considerably between countries. The aim of this communication is to provide an overview of the registered products, to analyse their real availability for clinical practice in the Czech Republic and Slovakia, to compare them with other European countries and to describe the main factors influencing their availability. |
| Related projects: |